Fonte: Il Messaggero
José Baselga, Executive Vice-President, R&D Oncology at AstraZeneca, announced that the distribution of the vaccine could start next spring. «It will be sold at cost price (roughly 2 euro)», he added. This forecast bodes well for the “Oxford-IRBM-AstraZeneca vaccine”. Piero Di Lorenzo, President of IRBM, is optimistic though cautious, and makes it clear that the vaccine will be safe: only the times of the bureaucracy will be shortened, not those of the scientific tests. «Currently the clinical trial is proceeding very well: there is no evidence to suggest any age or pathology-related contraindication», he added. «European coordination is crucial» to defeat Covid-19, told to Ansa Stella Kyriakides, European Commissioner for Health and Food Safety.
Article by Cristiana Mangani published on Il Mattino – 03/11/2020